Aridis Pharmaceuticals Profit Margin

Aridis Pharmaceuticals (ARDS) currently reports a profit margin of -3.16% as of September 2023. That compares with -4132.48% in the prior-year period — up 99.9% year over year. That is below the Healthcare sector average of 13.39%. Use the charts on this page to explore Aridis Pharmaceuticals's profit margin history and peer comparisons.

Aridis Pharmaceuticals's profit margin increased from -4132.48% to -3.16% — a 99.9% year-over-year increase (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Aridis Pharmaceuticals's profit margin of -3.16% is lower than the Healthcare sector average of 13.39%. That is roughly 123.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Aridis Pharmaceuticals's current -3.16% should be judged against Healthcare norms (sector average: 13.39%) and against ARDS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -3.16%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.39%. From there, open related valuation or income-statement pages for Aridis Pharmaceuticals, and consider following ARDS for alerts when major investors trade the stock.